home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Cancer Therapy Raises Hopes for Potentially Less Toxic Cancer Treatments in Humans

 
  January, 3 2001 11:54
your information resource in human molecular genetics
 
     
Encapsulating cancer therapies

A single injection of living drug "factories" can shrink tumors in mice by cutting off their blood supply, raising hopes for potentially less toxic cancer treatments in humans.

Tumor cells, which need oxygen and nutrients to continue to grow, stimulate the growth of networks of new blood vessels—a process called angiogenesis. In theory, cutting off the blood supply by blocking angiogenesis could stall the cancer’s growth or even kill it. However, natural angiogenesis inhibitors are not effective medicines because they are quickly degraded in the body. To overcome this obstacle, researchers have found a way to deliver the agent using cell "factories."

Teams led by Rona Carroll and Mary-Ann Read [Nature Biotechnology, Vol. 19, Issue 1, 01 Jan 2001] genetically engineered baby hamster kidney cells in the test tube to secrete endostatin, a natural angiogenesis inhibitor. The cells were then coated in a jelly-like substance, rendering them invisible to the host’s immune system but still able to "breathe." The capsules were then injected into mice to study their effect on glioblastoma, an aggressive form of cancer.

In Carroll’s study, just a single injection of the capsules close to a tumor that had been grown under the mouse’s skin reduced the weight of the tumor by over 70%. Read’s group took a different approach, injecting the capsules into the brain before a cancer was induced. In this case, a single injection slowed the growth of the cancer and prolonged survival of the rats by up to 70%. Although the cancer was not cleared completely by either approach, the work suggests that local delivery of angiogenesis inhibitors using living drug "factories" is feasible.

Contact:

Rona Carroll
Brigham and Women’s Hospital
Boston MA 02115
USA
Telephone: +1 617 278 0177

Tracy-Ann Read
Dept Anatomy and Cell Biology
University of Bergen
Norway
Telephone: +47 55 58 63 73
Email: Tracy-Ann.Read@PKI.UIB.NO

(News & Views)

Gabriele Bergers and Douglas Hanahan
Department of Biochemistry and Biophysics
Hormone Research Institute
Diabetes Center and Comprehensive Cancer Center
University of California
San Francisco, CA 94143-0534
USA
Telephone: +1 415 476 9209
Email: dh@biochem.ucsf.edu

(C) Nature Biotechnology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.